The American startup Synchron has launched clinical trials of the brain–computer interface Stentrode, designed to help paralyzed patients. This is reported by Bloomberg.
We’re proud to announce that we’ve achieved a significant milestone for our company and millions of people living with #paralysis. We’ve officially enrolled the first patient in our early feasibility study here in the US. To learn more https://t.co/vHRYtUx9z3 pic.twitter.com/XWtwh6kS4n
— Synchron (@synchroninc) May 4, 2022
Six patients from New York and Pittsburgh, Pennsylvania, will participate in the trial. One of them has already arrived at the hospital, but Synchron founder and CEO Tom Oxley declined to name him or provide demographic details.
In the initial phase, Stentrode must confirm its safety and demonstrate the ability to control digital devices without using hands.
Previously, Synchron had secured approvals for short-term lab studies. The company believes that if the trial is successful, the device could be approved for widespread long-term use.
Earlier in January, Neuralink opened a vacancy for a director of clinical trials.
In the same month, scientists developed an AI-based eye implant that restored the vision of a nearly blind woman.
In August 2021, Synchron received clearance from the U.S. Food and Drug Administration to conduct tests of neural interfaces in humans.
Subscribe to ForkLog news on Telegram: ForkLog AI — all the news from the world of AI!